Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript

Jun 22, 2020 / 09:00PM GMT
Release Date Price: $127.41 (-1.10%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Okay. I'm not sure if I'm supposed to read any kind of disclosures, but I'm going to go ahead and introduce myself. I'm Tazeen Ahmad. I'm one of the med biotech analysts here at Bank of America. It's my pleasure this afternoon to introduce our next presenting company, Neurocrine. Speaking for Neurocrine this afternoon is CEO, Kevin Gorman; and Kyle Gano, who is Chief Business Development and Strategy Officer.

Kevin and Kyle, good afternoon. Thanks for joining us.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Good afternoon, Tazeen. Thanks for having us.

Questions & Answers

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

So I think everyone that's joined us on this particular call is pretty familiar with Neurocrine already. So, Kevin, I won't ask you to do the 2-minute elevator pitch that we follow on this webcast. But I did want to get a sense, an update, if you will, on where you guys are currently as it

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot